EpirubicinAntineoplastic Combined Chemotherapy ProtocolsAntibiotics, AntineoplasticBreast NeoplasmsFluorouracilCyclophosphamideDrug Administration SchedulePaclitaxelTaxoidsChemotherapy, AdjuvantToxicity TestsCisplatinEarly Detection of CancerStomach NeoplasmsNeoplasm MetastasisSurvival AnalysisDisease-Free SurvivalDose-Response Relationship, DrugTreatment OutcomeAntineoplastic AgentsSurvival RateDeoxycytidineLung NeoplasmsRazoxaneOvarian NeoplasmsNeoplasmsProstatic NeoplasmsInfusions, IntravenousNeoplasm StagingDoxorubicinCombined Modality TherapyVinblastineAnthracyclinesDrug Resistance, NeoplasmColonic NeoplasmsGranulocyte Colony-Stimulating FactorFollow-Up StudiesReceptor, erbB-2Pancreatic NeoplasmsNeutropeniaAntineoplastic Agents, PhytogenicMethotrexateDisease ProgressionToxicity Tests, AcuteNeoplasm InvasivenessAdenocarcinomaNeoplasm Recurrence, LocalNeoadjuvant TherapyPrognosisProspective StudiesGene Expression Regulation, NeoplasticCell Line, TumorCarcinomaUrinary Bladder NeoplasmsMice, NudeTamoxifenReceptors, EstrogenHematologic DiseasesNeoplasm ProteinsCell SurvivalCarcinoma, Non-Small-Cell LungRetrospective StudiesTumor Markers, BiologicalEsophageal NeoplasmsAlopeciaCancer VaccinesMaximum Tolerated DoseCarboplatinAntimetabolites, AntineoplasticNauseaLiver NeoplasmsEtoposideIfosfamideLeukopeniaKaplan-Meier EstimateRisk AssessmentUterine Cervical NeoplasmsBone NeoplasmsReverse Transcriptase Polymerase Chain ReactionVomitingCarcinoma, Small CellCarcinoma, Squamous CellTime FactorsColorectal NeoplasmsRNA, MessengerGenetic Predisposition to DiseaseAntibodies, MonoclonalDrug EvaluationAntibodies, Monoclonal, HumanizedProlyl HydroxylasesReceptors, ProgesteroneNeoplasms, Second PrimaryXenograft Model Antitumor AssaysBiliary Tract NeoplasmsLeucovorinMutationMastectomyStomatitisApoptosisRisk